SAT-084 Comparative Analysis of Prolactinoma Presentation and Treatment in Hispanic and Non-Hispanic Patients: A Single-Center Retrospective Study

Abstract Disclosure: B. Hu: None. K.M. Brickner: None. V.L. Vargas: None. F.M. Acosta: None. S. Raghunathan: None. Introduction: Prolactinomas account for approximately 30-40% of all clinically diagnosed pituitary adenomas. There is a lack of research on differences in disease presentation, treatment, or management in the Hispanic population. This study aims to examine a subset of patients with prolactinomas at a tertiary referral center in South Texas. The purpose of our study was to assess treatment patterns and medication dosages, with the goal of identifying any disparities or trends specific to this demographic. Methods: We conducted a single-center, retrospective review of a population of patients who were diagnosed with hyperprolactinemia and/or prolactinoma between 2002-2024. The patients were categorized as self-reported Hispanic or Non-Hispanic/Other based on documentation in the medical record. Patients were treated medically with dopamine agonists (cabergoline or bromocriptine). Comparison sought between the two ethnic groups included drug of choice, pre-treatment prolactin levels, highest weekly treatment dose, and initial tumor size. Analysis was conducted with Student’s and Welch’s t-test. Results: 59 patients presenting with prolactinoma were studied (48.7 ± 17.3 years, 57.6% female). 26 (44.1%) of patients self-identified as Hispanic/Latino and 33 (55.9%) self-identified as Non-Hispanic/Non-Latino or Other. Hispanic patients had significantly lower starting prolactin levels (131.7 ng/mL ± 141.3 vs. 773.1 ng/mL ± 1465.5, p=0.04) and starting tumor sizes (8.9 mm ± 9.8 vs. 17.4 mm ± 16.8, p=0.04) compared to Non-Hispanic. 39 patients received medical treatment with cabergoline or bromocriptine. Of the Hispanic patients, 12 were treated with cabergoline and 4 were treated with bromocriptine. All 23 Non-Hispanic patients received cabergoline. No significant difference was observed between the two groups for highest weekly cabergoline dose (1.7 mg vs 0.9 mg, p=0.06). Conclusion: We found no significant difference in highest treatment dose between Hispanic and Non-Hispanic patients medically treated for prolactinoma. However, Hispanic patients presented with significantly lower starting prolactin levels and tumor sizes, suggesting potential differences in disease presentations. Of note, all patients receiving bromocriptine were Hispanic, which may reflect different treatment preferences, access, or provider decisions for these patients. These results highlight the need for further research into the unique characteristics of prolactinomas and treatment outcomes in Hispanic patients to promote equitable and individualized management within this population. *Beverly Hu, Kate Brickner, and Victoria Vargas contributed equally to this work. Presentation: Saturday, July 12, 2025